No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.
① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?
Hong Kong stocks are fluctuating | Kunbo Medical-B (02216) has risen over 12% again, with a cumulative increase of nearly 200% this month. The core product BroncAblate Zhiheng has been approved for上市.
Kunbo Medical-B (02216) rose over 12% in the morning session, with a cumulative increase of nearly twice in the month. As of the time of writing, it is up 10.2% at HKD 2.7, with a transaction value of HKD 12.7802 million.
Hong Kong Stock Market Midday Review | Hang Seng Index rose 1.36% in the morning session, Mainland Real Estate stocks all moved higher.
Citigroup strategists urge investors to increase Shareholding in Chinese Real Estate stocks, as policy support and better management practices are expected to enhance profitability in the industry.
BRONCUS-B: Annual Report 2024
Hong Kong Stock Concept Tracking | The country supports the innovative development of high-end Medical Devices machinery, and Institutions are Bullish on the continued recovery of the Medical Devices market (including concept stocks).
National Medical Products Administration: 308 medical instruments products were approved for registration in March.
Hong Kong stocks moving丨Kunbo Medical-B soared 41%, with the stock price reaching a nearly two-year high. The core product BroncAblate has been approved for sale in China.
Gelonghui April 22 | Kunbo Medical-B (2216.HK) opened high and rose today, at one point surging 41.5% to 1.5 Hong Kong dollars, reaching a nearly two-year high since May 30, 2023, and has increased more than 1.5 times this year. In terms of news, Kunbo Medical announced last night that its core product, the world's first natural cavity radiofrequency ablation device for lung cancer treatment, the BroncAblate Zhiheng disposable radiofrequency ablation catheter for the lungs, has officially been approved by the China National Medical Product Administration (NMPA) for sale in China, leading lung cancer treatment into ultra-minimally invasive interventional therapy.
